ANORO ELLIPTA Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving ANORO ELLIPTA Growth

1. First-mover advantage in once-daily dual bronchodilation

ANORO ELLIPTA was the first once-daily LAMA/LABA combination approved in the U.S. for COPD maintenance therapy. The drug combines umeclidinium and vilanterol in the ELLIPTA dry-powder inhaler, offering simplified once-daily administration and improved bronchodilation compared with monotherapy. GSK emphasized that ANORO provided a new treatment option for COPD patients requiring dual bronchodilator therapy in a single inhaler.

2. Large and expanding COPD patient population

COPD remains one of the world's leading chronic respiratory diseases, supporting long-term demand for maintenance bronchodilators. GSK cited National Heart, Lung, and Blood Institute estimates showing nearly 27 million people in the U.S. alone are affected by COPD. Aging populations, smoking exposure, occupational pollutants, and worsening air quality globally continue to expand the addressable patient population for long-acting inhaled therapies like ANORO.

3. Strong historical sales growth and market-share gains

ANORO demonstrated rapid commercial uptake during its launch years, validating physician acceptance of dual bronchodilation. In GSK's Q2 2017 results, ANORO sales increased 85% year over year to approximately £85 million, driven primarily by U.S. market-share gains. GSK also reported that BREO, ANORO, and INCRUSE all continued gaining U.S. market share during that period, helping offset declines from older respiratory products such as Advair/Seretide.

4. Synergy with GSK's broader ELLIPTA respiratory franchise

ANORO benefits strategically from GSK's large ELLIPTA ecosystem, which includes BREO, INCRUSE, and blockbuster triple therapy TRELEGY ELLIPTA. Physician familiarity with the ELLIPTA inhaler platform improves prescribing comfort and strengthens franchise loyalty across COPD treatment escalation pathways. GSK's Respiratory, Immunology & Inflammation business continues to grow strongly, with Respiratory/Immunology sales increasing 13% in FY2024 and 18% in FY2025. TRELEGY alone generated approximately £3.0 billion in 2025 sales, reinforcing the durability of the ELLIPTA platform overall.

5. Extensive clinical-development program supporting efficacy claims

ANORO's regulatory approvals were supported by large global clinical programs. The Australian approval announcement noted that evidence was based on 11 clinical studies involving approximately 7,851 COPD patients. Additional head-to-head studies comparing ANORO against SERETIDE/ADVAIR demonstrated superior bronchodilation outcomes, helping strengthen physician confidence in dual bronchodilator therapy.

ANORO ELLIPTA Recent Developments

ANORO ELLIPTA, approved by Japanese MHLW (Ministry of Health, Labour and Welfare) in July 2014 for COPD maintenance treatment.

"ANORO ELLIPTA Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of ANORO ELLIPTA for approved indication like Chronic obstructive pulmonary disease in the 7MM. A detailed picture of ANORO ELLIPTA's existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the ANORO ELLIPTA for approved indications. The ANORO ELLIPTA market report provides insights about ANORO ELLIPTA's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ANORO ELLIPTA performance, future market assessments inclusive of the ANORO ELLIPTA market forecast analysis for approved indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ANORO ELLIPTA sales forecasts, along with factors driving its market.

ANORO ELLIPTA Drug Summary

ANORO ELLIPTA is a once-daily dual bronchodilator therapy developed by GSK for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The drug combines umeclidinium, a long-acting muscarinic antagonist (LAMA), with vilanterol, a long-acting beta2-agonist (LABA), to provide complementary bronchodilation through two distinct mechanisms that relax airway smooth muscle and improve airflow. Delivered via the ELLIPTA dry powder inhaler device, ANORO ELLIPTA is designed to enhance lung function, reduce breathlessness, and improve overall symptom control in COPD patients with convenient once-daily dosing. Clinical trials have demonstrated significant improvements in forced expiratory volume (FEV1), exercise capacity, and quality of life compared with monotherapy bronchodilators, establishing ANORO ELLIPTA as a widely used maintenance option in COPD management. The report provides ANORO ELLIPTA's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ANORO ELLIPTA Market Report

The report provides insights into:

• A comprehensive product overview including the ANORO ELLIPTA MoA, description, dosage and administration, research and development activities in approved indication like Chronic obstructive pulmonary disease.
• Elaborated details on ANORO ELLIPTA regulatory milestones and other development activities have been provided in ANORO ELLIPTA market report.
• The report also highlights ANORO ELLIPTA's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The ANORO ELLIPTA market report also covers the patents information, generic entry and impact on cost cut.
• The ANORO ELLIPTA market report contains current and forecasted ANORO ELLIPTA sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ANORO ELLIPTA market report also features the SWOT analysis with analyst views for ANORO ELLIPTA in approved indications.

Methodology:

The ANORO ELLIPTA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ANORO ELLIPTA Analytical Perspective by DelveInsight

• In-depth ANORO ELLIPTA Market Assessment

This ANORO ELLIPTA sales market forecast report provides a detailed market assessment of ANORO ELLIPTA for approved indication like Chronic obstructive pulmonary disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ANORO ELLIPTA sales data uptil 2034.

• ANORO ELLIPTA Clinical Assessment

The ANORO ELLIPTA market report provides the clinical trials information of ANORO ELLIPTA for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

ANORO ELLIPTA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ANORO ELLIPTA Market Potential & Revenue Forecast

• Projected market size for the ANORO ELLIPTA and its key indications
• Estimated ANORO ELLIPTA sales potential (ANORO ELLIPTA peak sales forecasts)
• ANORO ELLIPTA Pricing strategies and reimbursement landscape

ANORO ELLIPTA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ANORO ELLIPTA Market positioning compared to existing treatments
• ANORO ELLIPTA Strengths & weaknesses relative to competitors

ANORO ELLIPTA Regulatory & Commercial Milestones

• ANORO ELLIPTA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ANORO ELLIPTA Clinical Differentiation

• ANORO ELLIPTA Efficacy & safety advantages over existing drugs
• ANORO ELLIPTA Unique selling points

ANORO ELLIPTA Market Report Highlights

• In the coming years, the ANORO ELLIPTA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ANORO ELLIPTA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ANORO ELLIPTA's dominance.
• Other emerging products for Chronic obstructive pulmonary disease are expected to give tough market competition to ANORO ELLIPTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ANORO ELLIPTA in approved indications.
• Analyse ANORO ELLIPTA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ANORO ELLIPTA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ANORO ELLIPTA in approved indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of ANORO ELLIPTA? How strong is ANORO ELLIPTA's clinical and commercial performance?
• What is ANORO ELLIPTA's clinical trial status in each individual indications such as Chronic obstructive pulmonary disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ANORO ELLIPTA Manufacturers?
• What are the key designations that have been granted to ANORO ELLIPTA for approved indications? How are they going to impact ANORO ELLIPTA's penetration in various geographies?
• What is the current and forecasted ANORO ELLIPTA market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ANORO ELLIPTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ANORO ELLIPTA for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is ANORO ELLIPTA? What is the duration of therapy and what are the geographical variations in cost per patient?